Search

Displaying results 1791 - 1800 of 8575 in total
  1. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of [melphalan]. … [A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].

  2. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. … It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness accompanying thromboangiitis obliterans in 1988; and for the treatment of subjective symptoms such as pain and

  3. Drug

    Piperonyl butoxide

    go.drugbank.com/drugs/DB09350
    ApprovedVet approved

    It has no pesticidal activity of its own, but acts to increase the activity of pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone. … Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is used for the treatment of head, pubic (crab), and body lice. Piperonyl butoxide is a synergist.

  4. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]

  5. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    [L53398] During studies, sugemalimab was well tolerated and has shown antitumor activity in multiple tumor types. … [L32868] Sugemalimab was under investigation in the clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma).

  6. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy. … [L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621]

  7. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    In February 2022, tepotinib was approved for use in Europe.[L42200] … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  8. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide.

  9. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    Camazepam also has less side effects, such as impaired cognition and reaction times, compared to other benzodiazepines. … In the United States camazepam is regulated as a Schedule IV controlled substance.

  10. Drug

    Glucagon

    go.drugbank.com/drugs/DB00040
    ApprovedInvestigational

    [L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631] … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.